Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atumelnant in pediatric classic congenital adrenal hyperplasia
2024-519578-38-00Phase 3Authorised
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 14
01
Overview
Phase 3, open-label trial of atumelnant in classic congenital adrenal hyperplasia and 21-hydroxylase deficiency (21-OHD) (3 arms), sponsored by Crinetics Pharmaceuticals. Planned start Mar 2026; status: authorised.
02
Drugs
atumelnant
03
Conditions
classic congenital adrenal hyperplasia21-hydroxylase deficiency (21-OHD)
Beyond the preview
Go deeper on 2024-519578-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519578-38-00.